Alterations in DNA copy number contribute to the development and progression of cancers and are common in epithelial tumors. We have used array Comparative Genomic Hybridization (aCGH) to visualize DNA copy number alterations across the genomes of lung tumors in the Kras LA2 model of lung cancer. Copy number gain involving the Kras locus, as focal amplification or whole chromosome gain, is the most common alteration in these tumors, and with a prevalence that increased significantly with increasing tumor size. Furthermore, Kras amplification was the only major genomic event among the smallest lung tumors, suggesting that this alteration occurs early during the development of mutant Kras driven lung cancers.
Introduction
The development of cancer is largely driven by progressive accumulation of genetic and epigenetic alterations, resulting in concerted deregulation of biological functions that together contribute to the cancer phenotypes. Alterations in DNA copy number are common in cancers, and especially in epithelial tumors. The gain or loss of DNA can occur focally and more often involves whole chromosomes or chromosomal arms (1, 2) . DNA amplification commonly occurs in regions containing proto-oncogenes whereas deletion frequently targets regions with tumor suppressor genes. In consequence, genomic regions with recurring focal alterations have emerged as genomic landmarks for discovery of genes with important functions in tumorigenesis and that are commonly altered in tumors (1) . The relevance of genomic imbalance is further underscored by the association between aneuploidy with disease aggressiveness in cancers of many tissues. Because molecular analyses have mostly focused on tumor tissues at relatively advanced stages, it has been difficult to formally study the evolution of genomic alterations during the natural course of tumor development.
Lung cancer is the second most common cancer in both men and women, and is responsible for the highest number of cancer-related deaths in the U.S. Adenocarcinoma is the most common subtype of lung cancer, accounting for 30-40% of the cases. Activating mutations in KRAS occur in ~30% of human lung adenocarcinomas and are associated with poor clinical outcome (3) . Studies in the mouse have demonstrated that oncogenic activation of Kras alone is sufficient for the initiation of lung tumors (4, 5) . In the Kras 4 Adult Kras LA2 mice develop multiple lung adenomas with a wide range in size that likely reflects the variable timing of the Kras activation and tumor initiation.
Previous analysis of genomic changes in tumors from the Kras LA2 mice were carried out on tumors from animals of mixed C57BL6 and 129/SvJae backgrounds (6) . These studies demonstrated some whole chromosome changes in a relatively small proportion of the tumors (27%) and noted the absence of any focal amplicons or deletions. We have transferred the 
Materials and Methods

Animals
Kras
LA2
mice on a C57BL6/129/SvJae background were backcrossed with FVB/N mice to create an Kras LA2 inbred line on the FVB/N strain background. The mice used in this study are in between generation N11 and N15. Animals were sacrificed at 6 months of age and their lung tissues were collected for molecular studies.
Tumor Genomic DNA Isolation
We isolated 83 lung tumors of different sizes from Kras LA2 mice. To avoid normal cell contamination, only the tumor mass inside the tumor capsule was used for DNA isolation.
Genomic DNA was extracted using the Dneasy Tissue kit (Qiagen) and further purified by phenol/choroform extraction. DNA concentrations were measured using a Biorad fluorometer.
Array Comparative Hybridization and Data Processing
aCGH arrays were prepared and printed as reported previously (7, 8) . Each array consisted 1056 BAC/P1 clones printed in quadruplicate (2 spatially separated duplicates) onto 3D-Link activated slides (Motorola Life Sciences) using a custom DNA arraying device developed at the UCSF Cancer Center. Two arrays, each 12 mm x 12 mm in size, were printed per slide. The identities and genomic coordinates of the BAC/P1 clones were based on the February 2002 freeze of the assembled mouse genome through the UCSC Genome Browser at http://genome.ucsc.edu. A detailed list of the clones including their associated markers and genomic coordinates were previously published online (7). We labeled 1 μg of test (tumor) DNA and reference genomic DNA (normal lung) with CY3 and CY5 (Amersham), respectively. DNA labeling, hybridization, slide imaging and data analyses were performed essentially as previously described (8) . The 16-bit TIFF images were collected using a custom-built CCD camera through CY3, CY5 and DAPI filters (9) . Images were segmented and quantified using custom software (10). Data were normalized to the median log 2 ratio of Cy3/Cy5. All clones except those mapping to chromosome six, known to be frequently altered in Kras 
Results
The Kras LA2 allele, originally on a C57BL6/129/SvJae mixed background, was backcrossed into the FVB/N background for more than 10 generations in order to minimize the effect of genetic heterogeneity on lung tumor development. Mice were sacrificed at 6 months of age, and a total of 83 surface lung tumors from more than 25 animals were obtained for molecular analyses. The size of the tumors was estimated based on their surface area measured at the time of resection. We categorized the tumors into four groups based on size (Table 1) .
Genomic DNA was isolated from the tumors and genome-wide DNA copy number alterations were quantified using aCGH. Histological analysis was performed on 27 of the tumors. The majority of these tumors (22 of 27) had a papillary histology (Fig. 1A) , as has been previously described (5) . Four tumors had a solid histology (Fig. 1B ), but these were relatively small (Categories 1 and 2) and we could not ascertain whether this pattern of growth was uniform throughout the tumor. Interestingly, one tumor had a mixture of both papillary and solid components. ). The level of focal amplification in these tumors was as high as fifteen-fold, and with very few, if any, copy number alteration in other parts of the genome. In three additional tumors in Category 1, more than 30% of the probes on chromosome six, including those overlapping with the Kras locus, showed a gain of a single copy that we interpreted to reflect a gain of the entire chromosome (Fig. 2B) . We conclude that gain of DNA copy number involving the Kras locus, either through focal amplification or whole chromosome gain, is the earliest detectable somatic alteration in oncogenic Kras-driven lung tumors.
Kras Amplification is an Early and Common Event in Lung Tumorigenesis
Somatic oncogenic activation of Kras initiates tumor formation in the Kras
Trisomy of chromosome six is the most common DNA copy number alteration across the four size categories of lung tumors. Of the 83 lung tumors analyzed, 49 (59%) had amplification of more than 30% of chromosome six probes ( Fig. 3A and Table 1 ). Importantly, the prevalence of chromosome six gain increased with increasing tumor size. The frequencies of trisomy of chromosome six ranged from 20% of Category 1 tumors to more than 80% of Category 4 tumors (P = 0.003, Chi-squared trend test; Table 1 ). When the threshold for calling trisomy was increased to 50% of probes, the number of tumors in each of the categories meeting this criterion decreased, but the trend between increasing tumor size and increasing incidence of trisomy six was maintained (P = 0.07, Chi-squared trend test). Probes overlapping the Kras locus were amplified in all tumors classified as having trisomy of chromosome six at both levels of stringency. These data suggest that gain of chromosome six, likely as a mechanism to up- Lung tumor progression is accompanied by increased genomic alterations.
While the genomes of the smallest tumors (Category 1) were relatively stable apart from changes on chromosome six (Fig. 2, 3B ), frequent gains and losses of DNA copy number were evident among larger tumors (Fig. 3C, D, E) . Considering all tumors together, we observed gains on chromosomes 1, 2, 8, 15, 17 and 19 as well as focal deletions or whole chromosomal loss on chromosomes 4, 5, 9 and 11 (Fig. 3A) . Because these events commonly involve whole chromosomes or relatively large chromosomal regions, it was not possible to determine with 
Discussion
We have used aCGH to generate a genome-wide view of DNA copy number alterations during the development and progression of mouse lung tumors in the Kras evidence of DNA copy number change was relatively small (6) . Importantly, the authors reported a lack of association between tumor size and genomic alterations (6) . In contrast, we observed a clear and significant increase in DNA copy number alterations with increasing tumor size (Fig 4A) . This correlation remained highly statistically significant even after chromosome six was removed from the analysis (Fig. 4B ). These data demonstrate the association of DNA copy number alterations with lung tumor progression in this model.
A likely explanation for the difference between our results and those of the prior study is that we have backcrossed the Kras LA2 allele into the FVB/N background for more than 10 generations whereas the allele was originally carried on a C57BL6/129/SvJae background (6).
On a C57BL6/129/SvJae background, approximately 30% of animals carrying the Kras LA2 allele developed skin papillomas or carcinomas and thymic lymphoma (5) but the incidence of these tumors on a FVB/N background is dramatically reduced (data not shown). This result was surprising, as FVB/N mice are known to be highly susceptible to development and progression of skin tumors initiated by activating mutations in the Hras gene (13, 14) . These observations suggest that although FVB/N mice are susceptible to Hras-driven skin tumors, they may be more resistant generally to activating mutations in Kras, including Kras mutant lung tumors.
Consequently, more genomic or genetic alterations may be required to drive Kras mutant lung tumor formation in this background. The relationship between frequency of genomic alterations and genetic background has also been observed in other murine models of cancer (15) . Data from analyses of mouse (16) activating Hras mutation commonly have gross chromosomal alterations that result in an increase in copy number of mutant Hras or loss of the wild-type (WT) Hras allele (11, 12).
Furthermore, the imbalance at the Hras locus contributes to the progression of squamous carcinomas to more invasive tumors (12) . We identified trisomy of chromosome six as the most common genomic alteration in lung adenomas from the Kras LA2 mice, particularly in the largest tumors, suggesting that genomic imbalance on this chromosome plays an important role in tumor progression. Interestingly, loss of heterozygosity spanning the KRAS locus has been reported in human lung cancer that correlates with KRAS mutation and preferentially targets the WT KRAS allele (19) . Genetic and in vitro studies have compellingly demonstrated that WT Kras can effectively attenuate the oncogenic effect of mutant Kras through mechanisms that remain to be elucidated (18, 20, 21) . We have further shown that the balance in expression levels of mutant and WT Kras is a major determinant of susceptibility to lung cancer development in the mouse (18) . Therefore, the imbalance in favor of mutant Kras in lung tumors, through gain of the mutant allele or loss of the WT allele, is compatible with the requirement of tumor cells to overcome the tumor suppressor effect of WT Kras.
The occurrence of focal amplification involving the Kras locus supports the notion that
Kras is the major driver of the genomic imbalance on chromosome six. The level of focal amplification was as high as 15-fold. However, focal amplification and especially high level of focal amplification of distal chromosome six was rare and occurred only in the smallest tumors (Category 1). Instead, the majority of tumors including many of the small tumors (Categories 1 and 2) have gained only a single copy of chromosome six. These data suggest that while Kras may be the main driver for genomic imbalance on chromosome six, the accompanying dosage increase of other chromosome six gene(s) may also contribute to lung tumor progression. 
Interestingly, both Braf and Raf1 (cRaf), well known downstream effectors of Ras signaling (22) , are also located on chromosome 6 and must therefore undergo copy number gains in lung tumors. Alternatively, a subtle increase in copy number, rather than high levels of amplification, is more compatible with the growth and progression of the tumors. Cellular senescence is an important barrier against tumorigenesis, and high levels of oncogenic Ras (23) 
